Sarepta signs plasmid supplier agreement after clinical trial hold

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/	Yok46233042)
(Image: Getty/ Yok46233042)
Sarepta signed a long-term agreement for the supply of plasmid DNA for its gene therapy program and the needs of any future programs.

The agreement between Sarepta and Aldevron, a plasmid DNA and gene editing enzymes supplier, will provide good manufacturing practice (GMP) grade plasmid for Sarepta’s micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program​ and limb-girdle muscular dystrophy (LGMD) programs.

Micro-dystrophin is a small portion of the gene, dystrophin, which individuals with DMD lack. Previous trials have shown positive results​ for the use of micro-dystrophin for the treatment of DMD.

Previously, Sarepta’s micro-dystrophin trial for the treatment of DMD was put on hold​ by the US Food and Drug Administration, after a DNA fragment was found within a plasmid used for the gene therapy. The plasmids supplied at the time were from an undisclosed third-party manufacturer.

The agreement with Aldevron will also provide plasmid source material for the company’s future gene therapy programs. Aldevron will help establish a supply chain for scalable manufacturing for Sarepta. An established supply chain, according to Doug Ingram, CEO of Sarepta, is one of the company’s strategic objectives.

Ingram further stated that, through this secure supply, “[the company] can accelerate and ensure robust patient access to our pipeline of promising gene therapies on an accelerated timeline.”

Related topics: Upstream Processing, Pipelines, Cell lines

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us


View more